Combined Use of Bevacizumab + Interferon A-2 α in the Treatement of Patients with Disseminated Kidney Cancer in Comparison with an Active Monitoring Group
Introduction. Despite the fact that the combined use of bevacizumab and interferon α -2A has been studied extensively and proved to be safe, there will always remain a group of patients for whom continuing the long-term drug treatment after a radical surgery would be unfeasible through personal reas...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2019-03-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/344 |